<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32645845</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Evidence for Anti-Viral Effects of Complete Freund's Adjuvant in the Mouse Model of Enterovirus Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">364</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines8030364</ELocationID><Abstract><AbstractText>Group B coxsackieviruses (CVBs) belonging to the genus, <i>Enterovirus</i> and contain six serotypes that induce various diseases, whose occurrence may involve the mediation of more than one serotype. We recently identified immunogenic epitopes within coxsackieviruses B3 (CVB3) viral protein 1 that induce anti-viral T cell responses in mouse models of CVB infections. In our investigations to determine the protective responses of the viral epitopes, we unexpectedly noted that animals immunized with complete Freund's adjuvant (CFA) alone and later challenged with CVB3 were completely protected against myocarditis. Similarly, the pancreatitis-inducing ability of CVB3 was remarkably reduced to only 10% in the CFA group as opposed to 73.3% in the control group that received no CFA. Additionally, no mortalities were noted in the CFA group, whereas 40% of control animals died during the course of 21 days post-infection with CVB3. Taken together, our data suggest that the adjuvant effects of CFA may be sufficient for protection against CVB infections. These observations may provide new insights into our understanding of the occurrence of viral infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gangaplara</LastName><ForeName>Arunakumar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6307-9391</Identifier><AffiliationInfo><Affiliation>School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Early Sickle Mortality Prevention, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massilamany</LastName><ForeName>Chandirasegaran</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Immuno-Oncology, CRISPR Therapeutics, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lasrado</LastName><ForeName>Ninaad</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6762-2654</Identifier><AffiliationInfo><Affiliation>School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steffen</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5166-2296</Identifier><AffiliationInfo><Affiliation>School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Jay</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4082-9254</Identifier><AffiliationInfo><Affiliation>School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>09SDG2010237</GrantID><Agency>American Heart Association</Agency><Country/></Grant><Grant><GrantID>HL114669</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>18TPA34170206</GrantID><Agency>American Heart Association</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BCG</Keyword><Keyword MajorTopicYN="N">CFA</Keyword><Keyword MajorTopicYN="N">adjuvant</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword></KeywordList><CoiStatement>The authors declare no financial or commercial conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32645845</ArticleId><ArticleId IdType="pmc">PMC7563290</ArticleId><ArticleId IdType="doi">10.3390/vaccines8030364</ArticleId><ArticleId IdType="pii">vaccines8030364</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., Van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:368&#x2013;381. doi: 10.1038/s41579-018-0022-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0022-3</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Noor A., Krilov L.R. Enterovirus Infections. Pediatr. Rev. 2016;37:505&#x2013;515. doi: 10.1542/pir.2016-0103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/pir.2016-0103</ArticleId><ArticleId IdType="pubmed">27909105</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M., Parker E.P.K., Grassly N.C. The epidemiology of non-polio enteroviruses: Recent advances and outstanding questions. Curr. Opin. Infect. Dis. 2015;28:479&#x2013;487. doi: 10.1097/QCO.0000000000000187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000187</ArticleId><ArticleId IdType="pmc">PMC6624138</ArticleId><ArticleId IdType="pubmed">26203854</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo D., Krogstad P. Enteroviruses in the early 21st century: New manifestations and challenges. Curr. Opin. Pediatr. 2016;28:107&#x2013;113. doi: 10.1097/MOP.0000000000000303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000000303</ArticleId><ArticleId IdType="pmc">PMC4750492</ArticleId><ArticleId IdType="pubmed">26709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley C.M., Watson J.T., Nix W.A., Curns A.T., Rogers S.L., Brown B.A., Conover C., Dominguez S.R., Feikin D.R., Gray S., et al. Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): A descriptive epidemiological investigation. Lancet Respir. Med. 2015;3:879&#x2013;887. doi: 10.1016/S2213-2600(15)00335-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(15)00335-5</ArticleId><ArticleId IdType="pmc">PMC5693332</ArticleId><ArticleId IdType="pubmed">26482320</ArticleId></ArticleIdList></Reference><Reference><Citation>Cihakova D., Rose N.R. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv. Immunol. 2008;99:95&#x2013;114. doi: 10.1016/S0065-2776(08)00604-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-2776(08)00604-4</ArticleId><ArticleId IdType="pubmed">19117533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaidane H., Hober D. Role of coxsackievirus B4 in the pathogenesis of type 1 diabetes. Diabetes Metab. 2008;34:537&#x2013;548. doi: 10.1016/j.diabet.2008.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2008.05.008</ArticleId><ArticleId IdType="pubmed">18951821</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N., Gangaplara A., Arumugam R., Massilamany C., Pokal S., Zhou Y., Xiang S.H., Steffen D., Reddy J. Identification of Immunogenic Epitopes That Permit the Detection of Antigen-Specific T Cell Responses in Multiple Serotypes of Group B Coxsackievirus Infections. Viruses. 2020;12:347. doi: 10.3390/v12030347.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12030347</ArticleId><ArticleId IdType="pmc">PMC7150766</ArticleId><ArticleId IdType="pubmed">32245257</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hagan D.T. Vaccine Adjuvants&#x2014;Preparation Methods and Research Protocols. Volume 42 Springer; Berlin, Germany: 2000.</Citation></Reference><Reference><Citation>Traub S., Von Aulock S., Hartung T., Hermann C. MDP and other muropeptides--direct and synergistic effects on the immune system. J. Endotoxin Res. 2006;12:69&#x2013;85. doi: 10.1179/096805106X89044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/096805106X89044</ArticleId><ArticleId IdType="pubmed">16690010</ArticleId></ArticleIdList></Reference><Reference><Citation>Su S.B., Silver P.B., Grajewski R.S., Agarwal R.K., Tang J., Chan C.C., Caspi R.R. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J. Immunol. 2005;175:6303&#x2013;6310. doi: 10.4049/jimmunol.175.10.6303.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.10.6303</ArticleId><ArticleId IdType="pubmed">16272281</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangaplara A., Massilamany C., Brown D.M., Delhon G., Pattnaik A.K., Chapman N., Rose N., Steffen D., Reddy J. Coxsackievirus B3 infection leads to the generation of cardiac myosin heavy chain-&#x3b1;-reactive CD4 T cells in A/J mice. Clin. immunol. 2012;144:237&#x2013;249. doi: 10.1016/j.clim.2012.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2012.07.003</ArticleId><ArticleId IdType="pubmed">22854287</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard J.R., Perry C.M., Harkins S., Lane T., Mena I., Asensio V.C., Campbell I.L., Whitton J.L. Coxsackievirus B3-induced myocarditis: Perforin exacerbates disease, but plays no detectable role in virus clearance. Am. J. Pathol. 1998;153:417&#x2013;428. doi: 10.1016/S0002-9440(10)65585-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65585-X</ArticleId><ArticleId IdType="pmc">PMC1852975</ArticleId><ArticleId IdType="pubmed">9708802</ArticleId></ArticleIdList></Reference><Reference><Citation>Crocker S.J., Frausto R.F., Whitmire J.K., Benning N., Milner R., Whitton J.L. Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. Am. J. Pathol. 2007;171:1762&#x2013;1773. doi: 10.2353/ajpath.2007.070179.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070179</ArticleId><ArticleId IdType="pmc">PMC2111101</ArticleId><ArticleId IdType="pubmed">18055551</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie E.L., Freund J. An Experimental Study of Protective Inoculation with Heat Killed Tubercle Bacilli. J. Exp. Med. 1937;66:761&#x2013;788. doi: 10.1084/jem.66.6.761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.66.6.761</ArticleId><ArticleId IdType="pmc">PMC2133531</ArticleId><ArticleId IdType="pubmed">19870697</ArticleId></ArticleIdList></Reference><Reference><Citation>Massilamany C., Gangaplara A., Steffen D., Reddy J. Identification of novel mimicry epitopes for cardiac myosin heavy chain-&#x3b1; that induce autoimmune myocarditis in A/J mice. Cell. Immunol. 2011;271:438&#x2013;449. doi: 10.1016/j.cellimm.2011.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2011.08.013</ArticleId><ArticleId IdType="pubmed">21939961</ArticleId></ArticleIdList></Reference><Reference><Citation>Massilamany C., Gangaplara A., Basavalingappa R.H., Rajasekaran R.A., Vu H., Riethoven J.J., Steffen D., Pattnaik A.K., Reddy J. Mutations in the 5&#x2019; NTR and the Non-Structural Protein 3A of the Coxsackievirus B3 Selectively Attenuate Myocarditogenicity. PLoS ONE. 2015;10:e0131052. doi: 10.1371/journal.pone.0131052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0131052</ArticleId><ArticleId IdType="pmc">PMC4476614</ArticleId><ArticleId IdType="pubmed">26098885</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard G.A. A New Test for 2 &#xd7; 2 Tables. Nature. 1945;156:177. doi: 10.1038/156177a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/156177a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D., Rose N.R. Coxsackievirus-induced myocarditis in mice: A model of autoimmune disease for studying immunotoxicity. Methods. 2007;41:118&#x2013;122. doi: 10.1016/j.ymeth.2006.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2006.07.009</ArticleId><ArticleId IdType="pmc">PMC1764911</ArticleId><ArticleId IdType="pubmed">17161308</ArticleId></ArticleIdList></Reference><Reference><Citation>Comoy E.E., Capron A., Thyphronitis G. Adjuvant is the major parameter influencing the isotype profiles generated during immunization with a protein antigen, the Schistosoma mansoni Sm28-GST. Scand. J. Immunol. 1998;47:444&#x2013;452. doi: 10.1046/j.1365-3083.1998.00330.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-3083.1998.00330.x</ArticleId><ArticleId IdType="pubmed">9627128</ArticleId></ArticleIdList></Reference><Reference><Citation>Leentjens J., Kox M., Stokman R., Gerretsen J., Diavatopoulos D.A., van Crevel R., Rimmelzwaan G.F., Pickkers P., Netea M.G. BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. J. Infect. Dis. 2015;212:1930&#x2013;1938. doi: 10.1093/infdis/jiv332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv332</ArticleId><ArticleId IdType="pubmed">26071565</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheid A., Borriello F., Pietrasanta C., Christou H., Diray-Arce J., Pettengill M.A., Joshi S., Li N., Bergelson I., Kollmann T., et al. Adjuvant Effect of Bacille Calmette-Guerin on Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn. Front. Immunol. 2018;9:29. doi: 10.3389/fimmu.2018.00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00029</ArticleId><ArticleId IdType="pmc">PMC5787546</ArticleId><ArticleId IdType="pubmed">29416539</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodmell D.L., Ewalt L.C. Enhanced resistance against encephalomyocarditis virus infection in mice, induced by a nonviable Mycobacterium tuberculosis oil-droplet vaccine. Infect. Immun. 1978;19:225&#x2013;230. doi: 10.1128/IAI.19.1.225-230.1978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.19.1.225-230.1978</ArticleId><ArticleId IdType="pmc">PMC414071</ArticleId><ArticleId IdType="pubmed">203533</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr S.E., Visintine A.M., Tomeh M.O., Nahmias A.J. Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection. Proc. Soc. Exp. Biol. Med. 1976;152:57&#x2013;60. doi: 10.3181/00379727-152-39327.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-152-39327</ArticleId><ArticleId IdType="pubmed">177992</ArticleId></ArticleIdList></Reference><Reference><Citation>Floch F., Werner G.H. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-guerin) Ann. Immunol. (Paris) 1976;127:173&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">180868</ArticleId></ArticleIdList></Reference><Reference><Citation>Moorlag S., Arts R.J.W., van Crevel R., Netea M.G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 2019;25:1473&#x2013;1478. doi: 10.1016/j.cmi.2019.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.04.020</ArticleId><ArticleId IdType="pubmed">31055165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathurin K.S., Martens G.W., Kornfeld H., Welsh R.M. CD4 T-Cell-Mediated Heterologous Immunity between Mycobacteria and Poxviruses. J. Virol. 2009;83:3528&#x2013;3539. doi: 10.1128/JVI.02393-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02393-08</ArticleId><ArticleId IdType="pmc">PMC2663272</ArticleId><ArticleId IdType="pubmed">19193795</ArticleId></ArticleIdList></Reference><Reference><Citation>Suenaga T., Okuyama T., Yoshida I., Azuma M. Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: Participation of interferon in enhanced resistance. Infect. Immun. 1978;20:312&#x2013;314. doi: 10.1128/IAI.20.1.312-314.1978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.20.1.312-314.1978</ArticleId><ArticleId IdType="pmc">PMC421853</ArticleId><ArticleId IdType="pubmed">208973</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 1997;186:1623&#x2013;1631. doi: 10.1084/jem.186.10.1623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.186.10.1623</ArticleId><ArticleId IdType="pmc">PMC2199137</ArticleId><ArticleId IdType="pubmed">9362523</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y., Conley F.K., Remington J.S. Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J. Immunol. 1989;143:2045&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pubmed">2506275</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B., Wang T., Samuel M.A., Whitby K., Craft J., Fikrig E., Diamond M.S. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 2006;80:5338&#x2013;5348. doi: 10.1128/JVI.00274-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00274-06</ArticleId><ArticleId IdType="pmc">PMC1472130</ArticleId><ArticleId IdType="pubmed">16699014</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagami H., Matsumoto T., Fujiwara N., Arakawa T., Kaneda K., Yano I., Kobayashi K. Trehalose 6,6&#x2019;-dimycolate (cord factor) of Mycobacterium tuberculosis induces foreign-body- and hypersensitivity-type granulomas in mice. Infect. Immun. 2001;69:810&#x2013;815. doi: 10.1128/IAI.69.2.810-815.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.69.2.810-815.2001</ArticleId><ArticleId IdType="pmc">PMC97956</ArticleId><ArticleId IdType="pubmed">11159972</ArticleId></ArticleIdList></Reference><Reference><Citation>Strachan D.P. Hay fever, hygiene, and household size. BMJ. 1989;299:1259&#x2013;1260. doi: 10.1136/bmj.299.6710.1259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.299.6710.1259</ArticleId><ArticleId IdType="pmc">PMC1838109</ArticleId><ArticleId IdType="pubmed">2513902</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada H., Kuhn C., Feillet H., Bach J.F. The &#x2018;hygiene hypothesis&#x2019; for autoimmune and allergic diseases: An update. Clin. Exp. Immunol. 2010;160:1&#x2013;9. doi: 10.1111/j.1365-2249.2010.04139.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2010.04139.x</ArticleId><ArticleId IdType="pmc">PMC2841828</ArticleId><ArticleId IdType="pubmed">20415844</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M.G., Joosten L.A., Latz E., Mills K.H., Natoli G., Stunnenberg H.G., O&#x2019;Neill L.A., Xavier R.J. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352:aaf1098. doi: 10.1126/science.aaf1098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1098</ArticleId><ArticleId IdType="pmc">PMC5087274</ArticleId><ArticleId IdType="pubmed">27102489</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M.G., Dominguez-Andres J., Barreiro L.B., Chavakis T., Divangahi M., Fuchs E., Joosten L.A.B., van der Meer J.W.M., Mhlanga M.M., Mulder W.J.M., et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 2020;20:375&#x2013;388. doi: 10.1038/s41577-020-0285-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0285-6</ArticleId><ArticleId IdType="pmc">PMC7186935</ArticleId><ArticleId IdType="pubmed">32132681</ArticleId></ArticleIdList></Reference><Reference><Citation>Netea M.G., van der Meer J.W. Trained Immunity: An Ancient Way of Remembering. Cell Host Microbe. 2017;21:297&#x2013;300. doi: 10.1016/j.chom.2017.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2017.02.003</ArticleId><ArticleId IdType="pubmed">28279335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleinnijenhuis J., Quintin J., Preijers F., Joosten L.A., Ifrim D.C., Saeed S., Jacobs C., van Loenhout J., de Jong D., Stunnenberg H.G., et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl. Acad. Sci. USA. 2012;109:17537&#x2013;17542. doi: 10.1073/pnas.1202870109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1202870109</ArticleId><ArticleId IdType="pmc">PMC3491454</ArticleId><ArticleId IdType="pubmed">22988082</ArticleId></ArticleIdList></Reference><Reference><Citation>van&#x2019;t Wout J.W., Poell R., van Furth R. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand. J. Immunol. 1992;36:713&#x2013;719. doi: 10.1111/j.1365-3083.1992.tb03132.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1992.tb03132.x</ArticleId><ArticleId IdType="pubmed">1439583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sher N.A., Chaparas S.D., Greenberg L.E., Bernard S. Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice. Infect. Immun. 1975;12:1325&#x2013;1330. doi: 10.1128/IAI.12.6.1325-1330.1975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.12.6.1325-1330.1975</ArticleId><ArticleId IdType="pmc">PMC415439</ArticleId><ArticleId IdType="pubmed">1107224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tribouley J., Tribouley-Duret J., Appriou M. Effect of Bacillus Callmette Guerin (BCG) on the receptivity of nude mice to Schistosoma mansoni. C. R. Seances Soc. Biol. Fil. 1978;172:902&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">157204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhtreiber W.M., Faustman D.L. BCG Therapy for Type 1 Diabetes: Restoration of Balanced Immunity and Metabolism. Trends Endocrinol. Metab. 2019;30:80&#x2013;92. doi: 10.1016/j.tem.2018.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2018.11.006</ArticleId><ArticleId IdType="pubmed">30600132</ArticleId></ArticleIdList></Reference><Reference><Citation>Faustman D.L. TNF, TNF inducers, and TNFR2 agonists: A new path to type 1 diabetes treatment. Diabetes Metab. Res. Rev. 2018;34 doi: 10.1002/dmrr.2941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.2941</ArticleId><ArticleId IdType="pubmed">28843039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristori G., Romano S., Cannoni S., Visconti A., Tinelli E., Mendozzi L., Cecconi P., Lanzillo R., Quarantelli M., Buttinelli C., et al. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology. 2014;82:41&#x2013;48. doi: 10.1212/01.wnl.0000438216.93319.ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000438216.93319.ab</ArticleId><ArticleId IdType="pmc">PMC3873620</ArticleId><ArticleId IdType="pubmed">24306002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristori G., Faustman D., Matarese G., Romano S., Salvetti M. Bridging the gap between vaccination with Bacille Calmette-Guerin (BCG) and immunological tolerance: The cases of type 1 diabetes and multiple sclerosis. Curr. Opin. Immunol. 2018;55:89&#x2013;96. doi: 10.1016/j.coi.2018.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2018.09.016</ArticleId><ArticleId IdType="pubmed">30447407</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaci M. The Protective Effect of the BCG Vaccine on the Development of Type 1 Diabetes in Humans. Value BCG TNF Autoimmun. 2014 doi: 10.1016/B978-0-12-799964-7.00004-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-799964-7.00004-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Shet A., Ray D., Malavige N., Santosham M., Bar-Zeev N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. medRxiv. 2020 doi: 10.1101/2020.04.01.20049478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.01.20049478</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller A., Reandelar M.J., Fasciglione K., Roumenova V., Li Y., Otazu G.H. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: An epidemiological study. medRxiv. 2020 doi: 10.1101/2020.03.24.20042937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.24.20042937</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen K.J., Karkov H.S., Lund N., Andersen A., Eriksen H.B., Barbosa A.G., Kantso B., Aaby P., Benn C.S. The immunological effects of oral polio vaccine provided with BCG vaccine at birth: A randomised trial. Vaccine. 2014;32:5949&#x2013;5956. doi: 10.1016/j.vaccine.2014.08.062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.062</ArticleId><ArticleId IdType="pubmed">25223267</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone K.M., Rue-Albrecht K., Magee D.A., Conlon K., Schubert O.T., Nalpas N.C., Browne J.A., Smyth A., Gormley E., Aebersold R., et al. Comparative &#x2019;omics analyses differentiate Mycobacterium tuberculosis and Mycobacterium bovis and reveal distinct macrophage responses to infection with the human and bovine tubercle bacilli. Microb. Genom. 2018;4 doi: 10.1099/mgen.0.000163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000163</ArticleId><ArticleId IdType="pmc">PMC5885015</ArticleId><ArticleId IdType="pubmed">29557774</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnier T., Eiglmeier K., Camus J.C., Medina N., Mansoor H., Pryor M., Duthoy S., Grondin S., Lacroix C., Monsempe C., et al. The complete genome sequence of Mycobacterium bovis. Proc. Natl. Acad. Sci. USA. 2003;100:7877&#x2013;7882. doi: 10.1073/pnas.1130426100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1130426100</ArticleId><ArticleId IdType="pmc">PMC164681</ArticleId><ArticleId IdType="pubmed">12788972</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann E., Sanz J., Dunn J.L., Khan N., Mendonca L.E., Pacis A., Tzelepis F., Pernet E., Dumaine A., Grenier J.C., et al. BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. Cell. 2018;172:176&#x2013;190. doi: 10.1016/j.cell.2017.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.12.031</ArticleId><ArticleId IdType="pubmed">29328912</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairweather D., Yusung S., Frisancho S., Barrett M., Gatewood S., Steele R., Rose N.R. IL-12 receptor beta 1 and Toll-like receptor 4 increase IL-1 beta- and IL-18-associated myocarditis and coxsackievirus replication. J. Immunol. 2003;170:4731&#x2013;4737. doi: 10.4049/jimmunol.170.9.4731.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.9.4731</ArticleId><ArticleId IdType="pubmed">12707353</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E., Nuwer M.R., Merigan T.C. Potentiating Effect of Freund&#x2019;s Adjuvant on Interferon Production by Endotoxin or Poly rI*Poly rC. Infect. Immun. 1970;2:69&#x2013;76. doi: 10.1128/IAI.2.1.69-76.1970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.2.1.69-76.1970</ArticleId><ArticleId IdType="pmc">PMC415966</ArticleId><ArticleId IdType="pubmed">16557802</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y., Rowe T., Leon A.J., Banner D., Danesh A., Xu L., Ran L., Bosinger S.E., Guan Y., Chen H., et al. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. J. Virol. 2010;84:8369&#x2013;8388. doi: 10.1128/JVI.02305-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02305-09</ArticleId><ArticleId IdType="pmc">PMC2919000</ArticleId><ArticleId IdType="pubmed">20534862</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Kaer L. Innate and virtual memory T cells in man. Eur. J. Immunol. 2015;45:1916&#x2013;1920. doi: 10.1002/eji.201545761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201545761</ArticleId><ArticleId IdType="pmc">PMC4540369</ArticleId><ArticleId IdType="pubmed">26013879</ArticleId></ArticleIdList></Reference><Reference><Citation>White J.T., Cross E.W., Burchill M.A., Danhorn T., McCarter M.D., Rosen H.R., O&#x2019;Connor B., Kedl R.M. Virtual memory T cells develop and mediate bystander protective immunity in an IL-15-dependent manner. Nat. Commun. 2016;7:11291. doi: 10.1038/ncomms11291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11291</ArticleId><ArticleId IdType="pmc">PMC4844673</ArticleId><ArticleId IdType="pubmed">27097762</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>